FDA Asked to Approve Talquetamab for Hard-to-treat Multiple Myeloma
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory multiple myeloma. “We look forward to working closely with the FDA in their review of the talquetamab submission,” Peter Lebowitz, MD, PhD, global oncology…